WebThe United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic … WebOct 7, 2024 · SAN DIEGO, Oct. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic medical device and technology company focused on unmet needs …

Aethlon Medical Announces U.S. FDA Approval of Hemopurifier …

WebEX-10.1 3 aethlon_8k-ex1001.htm FORM OF UNIT PURCHASE AGREEMENT . Exhibit 10.1 . UNIT PURCHASE AGREEMENT . UNIT PURCHASE AGREEMENT (this “Agreement”) made as of the date set forth on the signature page hereof between Aethlon Medical, Inc., a Nevada corporation (the “Company”), and the subscriber(s) identified on … WebSAN DIEGO, July 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat … michael persson gripkow

2024-04-11 OTCQB:SIGY Press Release Sigyn Therapeutics Inc

WebApr 11, 2024 · She also served as Director of Research at Aethlon Medical, Inc., where she oversaw preclinical programs that facilitated the first-in-human clinical investigation of the Aethlon Hemopurifier® as an adjunct therapy to enhance the benefit of pembrolizumab (Keytruda), an immuno-oncology drug approved by FDA to treat cancer. WebAug 9, 2024 · On July 6, 2024, the U.S. Food and Drug Administration (FDA) approved a supplement to our COVID-19 trial. The newly approved protocol supplement eliminates the inclusion criteria that... WebJun 25, 2013 · Aethlon Medical, Inc. (OTCQB: AEMD), announced today that the United States Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier@ in the United States. michael pertwee actor